Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.47
Price to sales ratio
2.71

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2824
DRUG
Bright Minds Biosciences Inc. - common stock
75.93 USD-2.45%+11.88%+22.76%+192.49%579.79 M USD
2835
IMMX
Immix Biopharma, Inc. - Common Stock
10.52 USD-5.31%-0.66%+22.61%+262.76%572.41 M USD
2893
ARVN
Arvinas, Inc. - Common Stock
8.10 USD-2.06%-7.85%+5.74%-12.90%522.62 M USD
2916
XOMA
XOMA Royalty Corporation - Common Stock
40.17 USD-9.16%-8.39%-3.99%+13.96%503.77 M USD

Frequently asked questions about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

What is the Ginkgo Bioworks Holdings, Inc. Class A Common Stock stock price today?

The current price of Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA) is 9.06. Over the past 24 hours, the stock has changed by -0.66%. Follow the DNA chart for real-time price dynamics.

What is the stock ticker of Ginkgo Bioworks Holdings, Inc. Class A Common Stock?

Ginkgo Bioworks Holdings, Inc. Class A Common Stock trades under the ticker DNA. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Ginkgo Bioworks Holdings, Inc. Class A Common Stock stock going up?

DNA has changed by -9.94% over the last week, +10.22% over the last month, and +2.03% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Ginkgo Bioworks Holdings, Inc. Class A Common Stock net income for the last quarter?

Ginkgo Bioworks Holdings, Inc. Class A Common Stock reported net income of -82.59 M for the last quarter. The previous quarter showed -80.75 M, which means net income changed by -2.27%.

How many employees does Ginkgo Bioworks Holdings, Inc. Class A Common Stock have?

As of the latest available data, Ginkgo Bioworks Holdings, Inc. Class A Common Stock has 485 employees. Workforce size can provide additional context about the company's scale and operations.

What is Ginkgo Bioworks Holdings, Inc. Class A Common Stock EBITDA?

Ginkgo Bioworks Holdings, Inc. Class A Common Stock EBITDA is -63.58 M, and its EBITDA margin is -275.59%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Ginkgo Bioworks Holdings, Inc. Class A Common Stock stock?

You can buy Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Ginkgo Bioworks Holdings, Inc. Class A Common Stock stock?

Investing in Ginkgo Bioworks Holdings, Inc. Class A Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the DNA chart and related analysis on metatrader.com as part of your research.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

News